renal cell carcinoma market

Key Highlights

• The treatment landscape for RCC has shifted towards immunotherapy and targeted therapies. Immune checkpoint inhibitors, such as pembrolizumab, have become central in both metastatic and adjuvant settings, offering improved survival outcomes for many patients, especially those with clear cell RCC, which accounts for about 75% of cases. 
• Targeted therapies like sunitinib, sorafenib, pazopanib, cabozantinib, axitinib, and lenvatinib (tyrosine kinase inhibitors) along with temsirolimus and everolimus (mTOR inhibitors) have proven effective for treating RCC.
• Approved therapies for RCC include immunotherapies such as KEYTRUDA and OPDIVO, as well as targeted agents like WELIREG, among others.
• Key companies such as Merck Sharp & Dohme, Xynomic Pharmaceuticals, Corvus Pharmaceuticals, Oncorena, and others are currently evaluating their lead asset for RCC. 

 

DelveInsight's "Renal cell carcinoma Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Renal cell carcinoma, historical and forecasted epidemiology as well as the Renal cell carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Renal cell carcinoma market report provides current treatment practices, emerging drugs, Renal cell carcinoma market share of the individual therapies, current and forecasted Renal cell carcinoma market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Renal cell carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Renal cell carcinoma market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2022-2036

Key Factors Driving the Market

• Increasing Adoption of Combination Therapies: The growing use of combination regimens such as immuno-oncology (IO) with tyrosine kinase inhibitors (TKIs) and IO–IO therapies has significantly improved progression-free survival and overall survival, driving treatment adoption.
• Rising Use of Immunotherapy and Targeted Therapies: The shift toward immune checkpoint inhibitors and targeted therapies has transformed RCC treatment, making them central to both first-line and advanced disease management.
• Growing Focus on Personalized Treatment Approaches: Advancements in biomarker-driven and patient-specific therapies are improving treatment selection, enhancing response rates, and optimizing clinical outcomes.
  

Renal cell carcinoma Disease Understanding and Treatment Algorithm

Renal cell carcinoma, cancerous cells form in the lining of the kidney tubules and expand into a tumour. The growth of this malignancy, like many others, begins modest and develops larger over time. It grows as a single mass most of the time. However, in some situations, a kidney may contain more than one tumour, or tumours may be discovered in both kidneys at the same time. Renal cell carcinoma symptoms normally do not occur until the tumour has grown to be big and metastatic. The most common renal cell carcinoma symptom is gross or microscopic hematuria, which is followed by flank pain, fever of undetermined origin (FUO), and a palpable lump. Hypertension can be caused by segmental ischemia or pedicle compression.Neoplastic disorders affect 20% of patients.

 

Renal cell carcinoma Diagnosis

A renal tumor is most typically discovered by chance during abdominal imaging (e.g., CT, ultrasonography). Before surgery, three-dimensional CT, CT angiography, or magnetic resonance angiography are used to identify the nature of renal cell carcinoma, more accurately determine the number of renal arteries present, and outline the vascular pattern.

 

Renal cell carcinoma Treatment

The treatment landscape for RCC has evolved significantly with the introduction of targeted therapies and immune checkpoint inhibitors (ICIs), which are now central to the management of advanced disease. Current treatment strategies are guided by disease stage and risk stratification, with localized RCC primarily managed through surgical approaches, while RCC is treated with systemic therapies including ICI–ICI combinations (e.g., Nivolumab + Ipilimumab) and ICI–TKI combinations (e.g., Pembrolizumab + Axitinib). Despite these advances, survival outcomes remain stage-dependent, with significantly lower 5-year survival rates (~15–18%) observed in patients with metastatic disease compared to localized disease. In selected patients with indolent and asymptomatic disease, active surveillance may be considered prior to initiating systemic therapy.

Renal cell carcinoma Epidemiology 

The Renal cell carcinoma epidemiology section provides insights about the historical and current Renal cell carcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Renal cell carcinoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Renal cell carcinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

• According to the American Cancer Society (2024), approximately 80,980 new cases of kidney cancer were diagnosed, including 52,410 in men and 28,570 in women. Kidney cancer accounts for approximately 4% of all new cancer cases in the United States, with incidence rates steadily increasing due to improved detection through imaging techniques.
• Globally, the age-standardized incidence rate (ASR) of kidney cancer is 4.6 per 100,000 population, with higher rates observed in males (6.1 per 100,000) compared to females (3.2 per 100,000). Renal cell carcinoma accounts for approximately 90% of all kidney cancer cases, with clear cell RCC being the most common subtype (~70%), followed by papillary RCC (10–15%) and chromophobe RCC (5%).
• Survival rates vary significantly by disease stage. Patients diagnosed with localized disease have a 5-year survival rate of approximately 93%, which decreases to 70% in regional disease and to around 13% in metastatic disease.

Renal cell carcinoma Recent Developments

• In February 2026, the US FDA accepted supplemental New Drug Applications (sNDAs) for the combination of belzutifan (WELIREG) and lenvatinib (LENVIMA) for advanced RCC following prior PD-1/PD-L1 therapy, with a PDUFA target action date of October 4, 2026.
• In February 2026, Merck and Eisai presented Phase III LITESPARK-011 results evaluating belzutifan plus lenvatinib in RCC at the ASCO Genitourinary Cancers Symposium.

Renal cell carcinoma Drug Chapters

The drug chapter segment of the Renal cell carcinoma report encloses the detailed analysis of Renal cell carcinoma marketed drugs and late-stage (Phase-III and Phase-II) Renal cell carcinoma pipeline drugs. It also helps to understand the Renal cell carcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Merck: KEYTRUDA

KEYTRUDA is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. In November 2021, the US FDA approved pembrolizumab for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. On 2019, the US FDA approved pembrolizumab (KEYTRUDA) in combination with axitinib for the first-line treatment of patients with RCC.

 

Merck: WELIREG

In December 2023, Merck announced that the US FDA approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with RCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

 

Casdatifan (AB521): Arcus Biosciences

Casdatifan is a small-molecule inhibitor of HIF-2a, a master switch that turns on hundreds of genes in response to low oxygen levels. In a majority of people with the most common form of kidney cancer (clear cell rcc), genetic anomalies result in the dysregulation of this master switch and transformation of normal kidney cells into cancerous ones. In February 2026, Arcus Biosciences reported updated Phase I/Ib data for casdatifan in previously treated advanced clear cell RCC, showing encouraging efficacy and supporting its continued clinical development in RCC, with a Phase III trial in first-line treatment targeted for initiation in 2026.

 

Zircaix (TLX250-CDx): Telix Pharmaceuticals

TLX250-CDx is an investigational PET imaging agent under development for the diagnosis and characterization of clear cell RCC. The company is also focusing on regulatory submissions for Pixclara and Zircaix in the United States to support potential 2026 launches, along with a planned Zircaix BLA (Biologic License Application) resubmission in the US.

 

Ciforadenant (CPI-444): Corvus Pharmaceuticals

Ciforadenant (CPI-444) is an investigational oral A2A receptor antagonist studied in RCC and other solid tumors. It targets adenosine-mediated immunosuppression in the tumor microenvironment to restore anti-tumor immune activity. Early clinical data in RCC suggest potential immune modulation, with preclinical studies showing synergy with PD-1 and CTLA-4 checkpoint inhibitors. In October 2025, Corvus Pharmaceuticals announced interim data from the Phase I/II clinical trial of ciforadenant in patients with RCC was presented as an oral presentation at the European Society for Medical Oncology (ESMO) Congress, highlighting early clinical evidence on its potential to modulate the tumor immune microenvironment.

 

Abexinostat: Xynomic Pharmaceuticals

Abexinostat is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM. It has been granted Fast Track designation (FTD) by the US FDA. The drug is in a global pivotal Phase III (NCT03592472, RENAVIV) of development for the treatment of RCC (in combination with pazopanib). No updates have been published on the company's website since 2019; however, the trial is still ongoing and being evaluated on clinical trial.

Renal cell carcinoma Market Outlook

The Renal cell carcinoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Renal cell carcinoma market trends by analyzing the impact of current Renal cell carcinoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Renal cell carcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Renal cell carcinoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Renal cell carcinoma market in 7MM is expected to witness a major change in the study period 2022-2036.

 

Key Findings

This section includes a glimpse of the Renal cell carcinoma market in 7MM.

 

The United States Market Outlook

This section provides the total Renal cell carcinoma market size and market size by therapies in the United States.

 

EU-5 Countries: Market Outlook

The total Renal cell carcinoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan Market Outlook

The total Renal cell carcinoma market size and market size by therapies in Japan is also mentioned.

Renal cell carcinoma Drugs Uptake

This section focuses on the rate of uptake of the potential Renal cell carcinoma drugs recently launched in the Renal cell carcinoma market or expected to get launched in the market during the study period 2022-2036. The analysis covers Renal cell carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Renal cell carcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Renal cell carcinoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Renal cell carcinoma Pipeline Development Activities

The Renal cell carcinoma report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Renal cell carcinoma key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The Renal cell carcinoma report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Renal cell carcinoma emerging therapies.

Reimbursement Scenario in Renal cell carcinoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Renal cell carcinoma market trends, we take KOLs and SMEs ' opinion working in the Renal cell carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Renal cell carcinoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Renal cell carcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Renal cell carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Renal cell carcinoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Renal cell carcinoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Renal cell carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Renal cell carcinoma market

Report Highlights

• In the coming years, the Renal cell carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Renal cell carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Renal cell carcinoma. The launch of emerging therapies will significantly impact the Renal cell carcinoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Renal cell carcinoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Renal cell carcinoma Report Insights

• Renal cell carcinoma Patient Population
• Therapeutic Approaches
• Renal cell carcinoma Pipeline Analysis
• Renal cell carcinoma Market Size and Trends
• Renal cell carcinoma Market Opportunities
• Impact of upcoming Renal cell carcinoma Therapies

Renal cell carcinoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Renal cell carcinoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Renal cell carcinoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Renal cell carcinoma Pipeline Product Profiles
• Renal cell carcinoma Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Renal cell carcinoma drug class share (%) distribution in 2022 and how it would look like in 2034?
• What would be the Renal cell carcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2022-2036)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Renal cell carcinoma market size during the forecast period (2022-2036)?
• At what CAGR, the Renal cell carcinoma market is expected to grow by 7MM during the forecast period (2022-2036)?
• What would be the Renal cell carcinoma market outlook across the 7MM during the forecast period (2022-2036)?
• What would be the Renal cell carcinoma market growth till 2036, and what will be the resultant market Size in the year 2036?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Renal cell carcinoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Renal cell carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Renal cell carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Renal cell carcinoma?
• Out of all 7MM countries, which country would have the highest prevalent population of Renal cell carcinoma during the forecast period (2022-2036)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2022-2036)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Renal cell carcinoma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Renal cell carcinoma in the USA, Europe, and Japan?
• What are the Renal cell carcinoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Renal cell carcinoma?
• How many therapies are in-development by each company for Renal cell carcinoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Renal cell carcinoma treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Renal cell carcinoma therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Renal cell carcinoma and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Renal cell carcinoma?
• What are the global historical and forecasted market of Renal cell carcinoma?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Renal cell carcinoma market
• To understand the future market competition in the Renal cell carcinoma market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Renal cell carcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Renal cell carcinoma market
• To understand the future market competition in the Renal cell carcinoma market